Literature DB >> 1861210

Mitochondrial encephalomyopathies in childhood. II. Clinical manifestations and syndromes.

M H Tulinius1, E Holme, B Kristiansson, N G Larsson, A Oldfors.   

Abstract

During a 4-year period 1984 to 1988, 20 children referred with manifestations of central nervous system or neuromuscular disease combined with hyperlactatemia were found to have a mitochondrial disease. Each diagnosis was based on the results of thorough biochemical and morphologic investigations. The patients were separated into one series with mainly encephalopathy (n = 14) and another with mainly myopathy (n = 6). The patients with encephalopathy had the following syndromes: Kearns-Sayre (n = 2), MERRF (myoclonus epilepsy and ragged red fibers; n = 2), MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes; n = 3), Alpers (n = 3), Leigh (n = 1), and other variants (n = 3). In patients with myopathy, three had hypertrophic nonobstructive cardiomyopathy. Ultrastructural abnormalities of mitochondria were the most common morphologic changes in the muscle biopsies. Complex I deficiency was most common in the patients with encephalopathy. All of the patients with myopathy had complex IV deficiency. Mutations of mitochondrial DNA were found in six patients with encephalopathy. We conclude that identification of defects at the DNA level and determination of the phenotypic expression with clinical, morphologic, and biochemical methods are fundamental for future rational classification of mitochondrial disorders.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861210     DOI: 10.1016/s0022-3476(05)80735-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Multiple presentation of mitochondrial disorders.

Authors:  A Nissenkorn; A Zeharia; D Lev; A Fatal-Valevski; V Barash; A Gutman; S Harel; T Lerman-Sagie
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

Review 2.  Genetic counselling and prenatal diagnosis in disorders of the mitochondrial energy metabolism.

Authors:  W Ruitenbeek; U Wendel; B C Hamel; J M Trijbels
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

3.  Absence of cytochrome c oxidase activity in a boy with dysfunction of renal tubules, brain and muscle.

Authors:  A M Das; S Schweitzer-Krantz; D J Byrd; J Brodehl
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

4.  Mitochondrial function in schimke-immunoosseous dysplasia.

Authors:  Thomas Lücke; Jochen H H Ehrich; Anibh M Das
Journal:  Metab Brain Dis       Date:  2005-09       Impact factor: 3.584

Review 5.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

6.  Tissue distribution and disease manifestations of the tRNA(Lys) A-->G(8344) mitochondrial DNA mutation in a case of myoclonus epilepsy and ragged red fibres.

Authors:  A Oldfors; E Holme; M Tulinius; N G Larsson
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

7.  Clinical presentations of mitochondrial cardiomyopathies.

Authors:  D Lev; A Nissenkorn; E Leshinsky-Silver; M Sadeh; A Zeharia; B-Z Garty; L Blieden; V Barash; T Lerman-Sagie
Journal:  Pediatr Cardiol       Date:  2004-06-08       Impact factor: 1.655

8.  Severe myoclonic epilepsy associated with mitochondrial cytopathy.

Authors:  M Castro-Gago; J Eirís; J Fernández-Bustillo; D Escribano; E Pintos; L Monasterio; J Peña
Journal:  Childs Nerv Syst       Date:  1995-11       Impact factor: 1.475

Review 9.  Cardiomyopathy in respiratory chain disorders.

Authors:  J Guenthard; F Wyler; B Fowler; R Baumgartner
Journal:  Arch Dis Child       Date:  1995-03       Impact factor: 3.791

10.  Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions.

Authors:  Emilio L Streck; Gabriela K Ferreira; Giselli Scaini; Gislaine T Rezin; Cinara L Gonçalves; Isabela C Jeremias; Alexandra I Zugno; Gustavo C Ferreira; Jeverson Moreira; Celine M Fochesato; Pedro R T Romão
Journal:  Neurochem Res       Date:  2011-03-02       Impact factor: 4.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.